Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersPredicting response to epigenetic therapyReassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposureDetailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma CellsEstablished and emerging targeted therapies in the myelodysplastic syndromes.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsArtesunate-enhanced apoptosis of human high-risk myelodysplastic cells induced by the DNA methyltransferase inhibitor decitabine.Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Epigenetic synergy between decitabine and platinum derivativesFive-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemiaDigging deep into "dirty" drugs - modulation of the methylation machinery.Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.The myelodysplastic syndrome as a prototypical epigenetic diseaseCDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancerHigh cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.Epigenetics of myelodysplastic syndromes.Novel drugs for older patients with acute myeloid leukemia.Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell linesEpigenetics: A primer for clinicians.Targeting the cancer epigenome for therapy.Epigenetic Determinants of Cancer.DNA Hypomethylating Drugs in Cancer Therapy.Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes.Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders.Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.Hypomethylation of let-7a-3 is associated with poor prognosis in myelodysplastic syndrome.Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.Choosing a hypomethylating agent in MDS: does gender matter?Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells
P2860
Q26743743-36EF663B-A435-4F11-96D1-D818531DDA25Q27027751-E31CDFDD-6029-40F3-B28A-E03737EA6E32Q28534843-49A0CB14-AAE0-4044-AC2A-17DC7786E73AQ28547322-A3E17FC7-6CB6-413A-945D-F5181C9E1C42Q30245476-7D0CE09B-2685-4CFE-89C8-72F29D3ACED2Q34398397-20D20FAA-431C-4CC1-8078-6314A0A74AF8Q35681469-EC181F7B-C214-41D0-A8A9-41EFAE061EA1Q35870211-A719A562-E75A-485B-A412-F53CA694518CQ36053915-B7CF133F-4DD6-499D-A353-04311ECBFE8DQ36290974-47BDE85A-D627-4F43-9617-A45FED9E2993Q36502385-8A4DF31C-5A82-45B4-A2DA-DDFB852CEB96Q36523796-DA904CE3-282C-486C-A787-6532A9B7CB7FQ36544042-3078E12C-DAFB-47F7-803B-579583715EECQ36654373-73020109-D728-4948-95FF-1EC786483F6EQ36833557-B381F21F-9FB0-41CC-8FA7-3755349F632DQ36899731-D203FE95-CC5C-4165-ADC9-4BDFFF2912D6Q37031262-4666A75C-F438-4B92-917A-74B94D408B09Q37627821-31334378-C295-4884-8ACC-B26521F0B1FBQ37994505-A915AA4B-FB1D-49B8-B10A-968B4B537606Q38160051-856F4975-555D-4290-98F6-7A2F321CC660Q38163846-CD401095-A711-437D-BDA3-06703D0596C1Q38241761-28CEA1C7-3717-4CD9-BFC2-B4ED9B2AFAF6Q38407057-4C9EFF47-4ACA-43C5-907F-27CC8A53DC94Q38762107-3CDCBC0E-7068-4924-86DE-B4424D734666Q38770916-1A1A3216-BE30-456D-B71F-36458485768EQ38821103-F7124632-5A3A-4ACA-BCE5-D170F91ED1DBQ38837858-948C3AB9-6414-4CCF-9871-6C419ED01813Q38979940-23B26AE4-841F-4C17-89FE-A94EFD5482E9Q39527812-47AEB1C6-B6EE-46D4-A241-847CC9048393Q47562352-45414959-7549-4EED-A03A-78E732786DB4Q49596672-FB3936D4-4313-4070-BC59-657EFC388A6DQ49711997-0DC80058-D4F4-44DE-A45C-6871F830FFC6Q53089094-44EB31EF-0DDC-4F7B-A79F-31555F122737Q53652472-044F8185-40AB-4419-AC09-4BD0822085AFQ53698496-07B480E4-167A-4D75-BBCD-FB2072E9769DQ53810338-AC66F151-6840-420F-B287-13120A30D564Q55433291-0AA25586-2657-46DA-95B7-C4B80012F8ADQ57461985-2DF5BFF3-75EB-4347-B31A-ECBFF75947DF
P2860
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
@ast
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
@en
type
label
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
@ast
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
@en
prefLabel
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
@ast
Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
@en
P2093
P2860
P50
P1433
P1476
Mechanisms of resistance to decitabine in the myelodysplastic syndrome
@en
P2093
Hagop M Kantarjian
Jaroslav Jelinek
Jingmin Shu
Nianxiang Zhang
Samih El Ahdab
Taichun Qin
Woonbok Chung
Xiaodan Wang
P2860
P304
P356
10.1371/JOURNAL.PONE.0023372
P407
P577
2011-08-17T00:00:00Z